Ocular Therapeutix Inc. (OCUL)
$10.73
$-0.18
(-1.61%)
As on 03-Sep-2026 10:37EDT
Market cap
$2,275 Mln
Revenue (TTM)
$52 Mln
P/E Ratio
--
P/B Ratio
4.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
-6.1
-
Debt to Equity
0.1
-
Book Value
$--
-
EPS
$-1.4
-
Face value
--
-
Shares outstanding
219,615,868
10 Years Aggregate
CFO
$-514.46 Mln
EBITDA
$-610.83 Mln
Net Profit
$-638.71 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ocular Therapeutix (OCUL)
| -11.7 | 31.3 | 29.1 | -15.6 | 40.5 | -0.8 | 5.3 |
|
BSE Sensex
| -10.1 | -2.5 | 2.0 | -5.0 | 5.2 | 5.7 | 10.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ocular Therapeutix (OCUL)
| 42.2 | 90.5 | 58.7 | -59.7 | -66.3 | 424.1 | -0.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ocular Therapeutix (OCUL)
|
10.7 | 2,275.2 | 52.1 | -301.5 | -557.2 | -51.3 | -- | 4.6 |
| 18.0 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 206.7 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 75.9 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 112.8 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.0 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.2 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 285.7 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 69.8 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 128.9 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Ocular Therapeutix (OCUL)
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The... company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Read more
-
President, CEO & Director
Mr. Antony Mattessich
-
President, CEO & Director
Mr. Antony Mattessich
-
Headquarters
Bedford, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ocular Therapeutix (OCUL)
What is the current share price of Ocular Therapeutix Inc (OCUL) Today?
The share price of Ocular Therapeutix Inc (OCUL) is $10.73 (NASDAQ) as of 03-Sep-2026 10:37 EDT. Ocular Therapeutix Inc (OCUL) has given a return of 40.46% in the last 3 years.
What is the current PB & PE ratio of Ocular Therapeutix Inc (OCUL)?
Since, TTM earnings of Ocular Therapeutix Inc (OCUL) is negative, P/E ratio is not available.
The P/B ratio of Ocular Therapeutix Inc (OCUL) is 4.57 times as on 28-Aug-2026, a 41 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-10.18 |
4.14 |
2024 |
-7.42 |
4.55 |
2023 |
-6.01 |
5.33 |
2022 |
-3.27 |
6.57 |
2021 |
-87.63 |
6.53 |
What is the 52 Week High and Low of Ocular Therapeutix Inc (OCUL)?
The 52-week high and low of Ocular Therapeutix Inc (OCUL) are Rs 16.44 and Rs 6.23 as of 03-Sep-2026.
What is the market cap of Ocular Therapeutix Inc (OCUL)?
Ocular Therapeutix Inc (OCUL) has a market capitalisation of $ 2,275 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ocular Therapeutix Inc (OCUL)?
Before investing in Ocular Therapeutix Inc (OCUL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.